Clinical Trial Update: D-Cycloserine for Serine Palmitoyltransferase Inhibition [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating D-Cycloserine as an inhibitor of Serine Palmitoyltransferase in hereditary spastic paraplegia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Spastic Paraplegia

Drugs mentioned

• D-cycloserine (D-cycloserine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hereditary Spastic Paraplegia | Phase 4 | Status: COMPLETED